Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

被引：15

作者：

Till, Brian G. ^{[1
]}

Park, Steven I. ^{[2
]}

Popplewell, Leslie L. ^{[3
]}

Goy, Andre ^{[4
]}

Penuel, Elicia ^{[5
]}

Venstrom, Jeffrey M. ^{[5
]}

Liu, Bo ^{[5
]}

Fingerle-Rowson, Guenter ^{[6
]}

Byon, John ^{[5
]}

Woodard, Paul ^{[5
]}

Palomba, M. Lia ^{[7
]}

机构：

[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA

[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

[3] City Hope Natl Med Ctr, Duarte, CA 91010 USA

[4] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[5] Genentech Inc, San Francisco, CA 94080 USA

[6] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland

[7] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY 10021 USA

来源：

关键词：

D O I：

10.1182/blood.V126.23.5104.5104

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3